Circulating secretory phospholipase A2 activity predicts recurrent events in patients with severe acute coronary syndromes

Journal of the American College of Cardiology

Volumn 46, Issue 7, 2005, Pages 1249-1257

  Mallat, Ziad ^a,e   Steg, Ph Gabriel ^b   Benessiano, Joëlle ^b   Tanguy, Marie Laure ^c   Fox, Keith A ^h   Collet, Jean Philippe ^d   Dabbous, Omar H ⁱ   Henry, Patrick ^e   Carruthers, Kathryn F ^h   Dauphin, Anne ^b   Arguelles, Carla Sibella ^b   Masliah, Joëlle ^f   Hugel, Bénédicte ^a,g   Montalescot, Gilles ^d   Freyssinet, Jean Marie ^a,g   Asselain, Bernard ^c   Tedgui, Alain ^a  

^a INSERM   (France)

^b BICHAT HOSPITAL   (France)

^c INSTITUT CURIE   (France)

^d PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^e HÔPITAL LARIBOISIÈRE   (France)

^f HÔPITAL SAINT ANTOINE   (France)

^g UNIVERSITÉ DE STRASBOURG   (France)

^h UNIVERSITY OF EDINBURGH   (United Kingdom)

ⁱ UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

C REACTIVE PROTEIN; INTERLEUKIN 18; PHOSPHOLIPASE A2;

ACUTE HEART FAILURE; ADULT; ARTICLE; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME;

ACUTE DISEASE; ANGINA, UNSTABLE; C-REACTIVE PROTEIN; FEMALE; HUMANS; INTERLEUKIN-18; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PHOSPHOLIPASES A; PROGNOSIS; RECURRENCE; SEVERITY OF ILLNESS INDEX;

EID: 27744559966     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2005.06.056     Document Type: Article

References (45)

1. E.A. Dennis Diversity of group types, regulation, and function of phospholipase A2 J Biol Chem 269 1994 13057 13060
2. L.S. Elinder, A. Dumitrescu, P. Larsson, U. Hedin, J. Frostegard, H.E. Claesson Expression of phospholipase A2 isoforms in human normal and atherosclerotic arterial wall Arterioscler Thromb Vasc Biol 17 1997 2257 2263
3. B. Ivandic, L.W. Castellani, X.P. Wang Role of group II secretory phospholipase A2 in atherosclerosis: 1. Increased atherogenesis and altered lipoproteins in transgenic mice expressing group IIa phospholipase A2 Arterioscler Thromb Vasc Biol 19 1999 1284 1290
4. K. Kugiyama, Y. Ota, K. Takazoe Circulating levels of secretory type II phospholipase A(2) predict coronary events in patients with coronary artery disease Circulation 100 1999 1280 1284
5. P.Y. Liu, Y.H. Li, W.C. Tsai Prognostic value and the changes of plasma levels of secretory type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention Eur Heart J 24 2003 1824 1832
6. K. Kugiyama, Y. Ota, S. Sugiyama Prognostic value of plasma levels of secretory type II phospholipase A2 in patients with unstable angina pectoris Am J Cardiol 86 2000 718 722
7. GRACE Investigators Rationale and design of the GRACE (Global Registry of Acute Coronary Events) Project a multinational registry of patients hospitalized with acute coronary syndromes Am Heart J 141 2001 190 199
8. P.G. Steg, R.J. Goldberg, J.M. Gore Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE) Am J Cardiol 90 2002 358 363
9. P.G. Steg, O.H. Dabbous, L.J. Feldman Determinants and prognostic impact of heart failure complicating acute coronary syndromes observations from the Global Registry of Acute Coronary Events (GRACE) Circulation 109 2004 494 499
10. F. Radvanyi, L. Jordan, F. Russo-Marie, C. Bon A sensitive and continuous fluorometric assay for phospholipase A2 using pyrene-labeled phospholipids in the presence of serum albumin Anal Biochem 177 1989 103 109
11. P. Pernas, J. Masliah, J.L. Olivier, C. Salvat, T. Rybkine, G. Bereziat Type II phospholipase A2 recombinant overexpression enhances stimulated arachidonic acid release Biochem Biophys Res Commun 178 1991 1298 1305
12. K.A. Eagle, M.J. Lim, O.H. Dabbous A validated prediction model for all forms of acute coronary syndrome estimating the risk of 6-month postdischarge death in an international registry JAMA 291 2004 2727 2733
13. J.T. Willerson, P.M. Ridker Inflammation as a cardiovascular risk factor Circulation 109 2004 II2 II10
14. M.L. Brennan, M.S. Penn, F. Van Lente Prognostic value of myeloperoxidase in patients with chest pain N Engl J Med 349 2003 1595 1604
15. G. Liuzzo, L.M. Biasucci, J.R. Gallimore The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina N Engl J Med 331 1994 417 424
16. D.A. Morrow, N. Rifai, E.M. Antman C-reactive protein is a potent predictor of mortality independently of and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. Thrombolysis In Myocardial Infarction J Am Coll Cardiol 31 1998 1460 1465
17. C. Heeschen, C.W. Hamm, J. Bruemmer, M.L. Simoons Predictive value of reactive protein and troponin T in patients with unstable angina: a comparative analysis. CAPTURE Investigators. Chimeric c7E3 AntiPlatelet Therapy in Unstable angina REfractory to standard treatment trial J Am Coll Cardiol 35 2000 1535 1542
18. B. Lindahl, H. Toss, A. Siegbahn, P. Venge, L. Wallentin Markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. FRISC Study Group. Fragmin during Instability in Coronary Artery Disease N Engl J Med 343 2000 1139 1147
19. S.K. James, B. Lindahl, A. Siegbahn N-terminal probrain natriuretic peptide and other risk markers for the separate prediction of mortality and subsequent myocardial infarction in patients with unstable coronary artery disease a Global Utilization of Strategies To Open occluded arteries (GUSTO)-IV substudy Circulation 108 2003 275 281
20. C. Mueller, H.J. Buettner, J.M. Hodgson Inflammation and long-term mortality after non-ST elevation acute coronary syndrome treated with a very early invasive strategy in 1042 consecutive patients Circulation 105 2002 1412 1415
21. M.N. Zairis, S.J. Manousakis, A.S. Stefanidis C-reactive protein levels on admission are associated with response to thrombolysis and prognosis after ST-segment elevation acute myocardial infarction Am Heart J 144 2002 782 789
22. M. Bennermo, C. Held, A. Hamsten Prognostic value of plasma C-reactive protein and fibrinogen determinations in patients with acute myocardial infarction treated with thrombolysis J Intern Med 254 2003 244 250
23. H. Benamer, P.G. Steg, J. Benessiano Comparison of the prognostic value of C-reactive protein and troponin I in patients with unstable angina pectoris Am J Cardiol 82 1998 845 850
24. Z. Mallat, A. Corbaz, A. Scoazec Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability Circ Res 89 2001 E41 E45
25. Z. Mallat, A. Corbaz, A. Scoazec Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability Circulation 104 2001 1598 1603
26. S.C. Whitman, P. Ravisankar, A. Daugherty Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-gamma Circ Res 90 2002 E34 E38
27. S. Blankenberg, L. Tiret, C. Bickel Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina Circulation 106 2002 24 30
28. S. Blankenberg, G. Luc, P. Ducimetiere Interleukin-18 and the risk of coronary heart disease in European men the Prospective Epidemiological Study of Myocardial Infarction (PRIME) Circulation 108 2003 2453 2459
29. E.L. Mangin Jr., K. Kugiyama, J.H. Nguy, S.A. Kerns, P.D. Henry Effects of lysolipids and oxidatively modified low density lipoprotein on endothelium-dependent relaxation of rabbit aorta Circ Res 72 1993 161 166
30. W. Pruzanski, P. Vadas Phospholipase A2 - a mediator between proximal and distal effectors of inflammation Immunol Today 12 1991 143 146
31. M. Murakami, I. Kudo, K. Inoue Secretory phospholipases A2 J Lipid Mediat Cell Signal 12 1995 119 130
32. M. Menschikowski, M. Kasper, P. Lattke Secretory group II phospholipase A2 in human atherosclerotic plaques Atherosclerosis 118 1995 173 181
33. E. Hurt-Camejo, S. Andersen, R. Standal Localization of nonpancreatic secretory phospholipase A2 in normal and atherosclerotic arteries. Activity of the isolated enzyme on low-density lipoproteins Arterioscler Thromb Vasc Biol 17 1997 300 309
34. T. Nakano, H. Arita Enhanced expression of group II phospholipase A2 gene in the tissues of endotoxin shock rats and its suppression by glucocorticoid FEBS Lett 273 1990 23 26
35. M. Murakami, I. Kudo, K. Inoue Molecular nature of phospholipases A2 involved in prostaglandin I2 synthesis in human umbilical vein endothelial cells. Possible participation of cytosolic and extracellular type II phospholipases A2 J Biol Chem 268 1993 839 844
36. H. Kuwata, Y. Nakatani, M. Murakami, I. Kudo Cytosolic phospholipase A2 is required for cytokine-induced expression of type IIA secretory phospholipase A2 that mediates optimal cyclooxygenase-2-dependent delayed prostaglandin E2 generation in rat 3Y1 fibroblasts J Biol Chem 273 1998 1733 1740
37. N. Leitinger, A.D. Watson, S.Y. Hama Role of group II secretory phospholipase A2 in atherosclerosis: 2. Potential involvement of biologically active oxidized phospholipids Arterioscler Thromb Vasc Biol 19 1999 1291 1298
38. C.J. Binder, M.K. Chang, P.X. Shaw Innate and acquired immunity in atherogenesis Nat Med 8 2002 1218 1226
39. O. Fourcade, M.F. Simon, C. Viode Secretory phospholipase A2 generates the novel lipid mediator lysophosphatidic acid in membrane microvesicles shed from activated cells Cell 80 1995 919 927
40. J.T. Swarthout, H.W. Walling Lysophosphatidic acid receptors, signaling and survival Cell Mol Life Sci 57 2000 1978 1985
41. N. Kume, M.I. Cybulsky, M.A. Gimbrone Jr Lysophosphatidylcholine, a component of atherogenic lipoproteins, induces mononuclear leukocyte adhesion molecules in cultured human and rabbit arterial endothelial cells J Clin Invest 90 1992 1138 1144
42. O. Fourcade, F. Le Balle, J. Fauvel, M.F. Simon, H. Chap Regulation of secretory type-II phospholipase A2 and of lysophosphatidic acid synthesis Adv Enzyme Regul 38 1998 99 107
43. Z. Mallat, B. Hugel, J. Ohan, G. Leséche, J.M. Freyssinet, A. Tedgui Shed membrane microparticles with procoagulant potential in human atherosclerotic plaques. A role for apoptosis in plaque thrombogenicity Circulation 99 1999 348 353
44. Z. Mallat, H. Benamer, B. Hugel Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes Circulation 101 2000 841 843
45. D.A. Morrow, N. Rifai, E.M. Antman Serum amyloid A predicts early mortality in acute coronary syndromes A TIMI 11A substudy J Am Coll Cardiol 35 2000 358 362